EyePoint Reports Data on DURAVYU Phase 3 Trial for Wet AMD
Topline results from the LUCIA phase 3 trial for DURAVYU failed to meet the primary endpoint for statistical non-inferiority, while demonstrating a successful safety profile and a 38% reduction in injections.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed